<turbo-stream action="append" target="audio_clips_list"><template>
    <hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8141199-part-2-of-5-top-10-oncogenic-markers-in-nsclc-for-2022-an-interview-with-david-gandara-md"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/39536821/75x75/c 75w, https://audioboom.com/i/39536821/150x150/c 150w, https://audioboom.com/i/39536821/300x300/c 300w, https://audioboom.com/i/39536821/600x600/c 600w, https://audioboom.com/i/39536821/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #130c1f; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/39536821/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S1 Ep8: Part 2 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with David Gandara MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available o...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
8m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1660767580" data-format="short_date">Aug 17, 2022</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
8m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8141198-part-3-of-5-top-10-oncogenic-markers-in-nsclc-for-2022-an-interview-with-charu-aggarwal-md-mph"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/39536821/75x75/c 75w, https://audioboom.com/i/39536821/150x150/c 150w, https://audioboom.com/i/39536821/300x300/c 300w, https://audioboom.com/i/39536821/600x600/c 600w, https://audioboom.com/i/39536821/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #130c1f; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/39536821/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S1 Ep8: Part 3 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Charu Aggarwal MD, MPH
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available o...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
6m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1660767511" data-format="short_date">Aug 17, 2022</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
6m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8141196-part-4-of-5-top-10-oncogenic-markers-in-nsclc-for-2022-an-interview-with-julia-rotow-md"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/39536821/75x75/c 75w, https://audioboom.com/i/39536821/150x150/c 150w, https://audioboom.com/i/39536821/300x300/c 300w, https://audioboom.com/i/39536821/600x600/c 600w, https://audioboom.com/i/39536821/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #130c1f; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/39536821/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S1 Ep8: Part 4 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Julia Rotow MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available o...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
17m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1660767458" data-format="short_date">Aug 17, 2022</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
17m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8141195-part-5-of-5-top-10-oncogenic-markers-in-nsclc-for-2022-an-interview-with-balazs-halmos-md-ms"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/39536821/75x75/c 75w, https://audioboom.com/i/39536821/150x150/c 150w, https://audioboom.com/i/39536821/300x300/c 300w, https://audioboom.com/i/39536821/600x600/c 600w, https://audioboom.com/i/39536821/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #130c1f; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/39536821/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S1 Ep7: Part 5 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Balazs Halmos MD, MS
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available o...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
10m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1660767396" data-format="short_date">Aug 17, 2022</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
10m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8116166-tumor-board-bridging-current-practices-and-new-therapeutic-developments-in-er-positive-breast-c"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/39399394/75x75/c 75w, https://audioboom.com/i/39399394/150x150/c 150w, https://audioboom.com/i/39399394/300x300/c 300w, https://audioboom.com/i/39399394/600x600/c 600w, https://audioboom.com/i/39399394/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #030d23; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/39399394/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S1 Ep6:  Tumor Board: Bridging Current Practices and New Therapeutic Developments in ER-Positive Breast Cancer
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
During this educational Tumor Board, breast cancer specialists will showcase challenging scenarios in metastatic and non-metastatic HR+ disease and contextualize data from pivotal clinical trials to optimize decision-making for patients with HR+/HER2- breast cancer.

Featuring: 
Fátima Cardoso, MD

Director, Breast Unit

Champalimaud Clinical Center

Lisbon, Portugal

 

Mario Campone, MD, PhD
...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
49m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1657138271" data-format="short_date">Jul 06, 2022</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
49m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8069229-managing-your-patients-with-ckd"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/39140116/75x75/c 75w, https://audioboom.com/i/39140116/150x150/c 150w, https://audioboom.com/i/39140116/300x300/c 300w, https://audioboom.com/i/39140116/600x600/c 600w, https://audioboom.com/i/39140116/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #030d23; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/39140116/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S1 Ep5: Managing Your Patients with CKD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
After you listen to this podcast, go to https://www.gotoper.com/2022consckd to learn more and get CME credit!
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
45m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1650383220" data-format="short_date">Apr 19, 2022</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
45m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8060503-what-you-need-to-know-about-the-evolving-role-of-til-therapy-in-cancer-treatment"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/39092227/75x75/c 75w, https://audioboom.com/i/39092227/150x150/c 150w, https://audioboom.com/i/39092227/300x300/c 300w, https://audioboom.com/i/39092227/600x600/c 600w, https://audioboom.com/i/39092227/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #030d22; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/39092227/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S1 Ep4: What You Need to Know About the Evolving Role of TIL Therapy in Cancer Treatment
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Tumor-infiltrating lymphocyte (TIL) is an emerging therapy that may one day change the approach to the management of solid tumors including melanoma, NSCLC, and more. Join us for a conversation with Dr. Omid Hamid, one of the principal investigators pioneering TIL therapy in clinical trials, as we discuss this novel treatment method. Dr. Hamid will break down what the community physician needs ...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
23m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1649101860" data-format="short_date">Apr 04, 2022</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
23m
</div>
</div>
</div>
</a></div>

</template></turbo-stream>
  <turbo-stream action="remove" target="audio_clips_pagination"></turbo-stream>
